Dan Primack
Fortune
Wall Street is killing Big Pharma’s future, said Dan Primack. When Pfizer announced this year that it was slashing spending on research and development, its shares rose more than 5 percent. When rival Merck said it was keeping its R&D spending level, its shares fell 3 percent. The message was clear: “Stop spending so much money to create new drugs.” Investors apparently believe it’s cheaper for pharmaceutical giants to get promising new medicines by buying start-ups. But that’s a dangerous elevation of “short-term dollars” over “long-term sense.”
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Already, the venture capital that fuels those start-ups and “drives new drug development” is running dry. This year, 17 percent fewer early-stage start-ups received VC funding than did so last year. And some major VC firms are abandoning the pharma sector altogether, saying the FDA’s drug-approval process is too long and uncertain.
If Big Pharma continues to slash R&D budgets, we’ll face “a looming imbalance” as the demand for new drugs far outstrips supply. Big Pharma needs to spend whatever it takes to improve Americans’ health instead of “succumbing to Wall Street’s worst instincts.”
-
Political cartoons for October 26Cartoons Sunday’s editorial cartoons include Young Republicans group chat, Louvre robbery, and more
-
Why Britain is struggling to stop the ransomware cyberattacksThe Explainer New business models have greatly lowered barriers to entry for criminal hackers
-
Greene’s rebellion: a Maga hardliner turns against TrumpIn the Spotlight The Georgia congresswoman’s independent streak has ‘not gone unnoticed’ by the president
-
Issue of the week: Car dealers’ showdown with Teslafeature Tesla's direct-sale business model is coming under fire in New Jersey and many other states.
-
Issue of the week: Has Washington defeated Wall Street?
feature The Dodd-Frank Act forced banks to sell off “many of their classic ‘Wall Street’ businesses. How are the banks doing?
-
Issue of the week: Is 2014 the recovery year?
feature Economic forecasters generally think 2014 will “be a breakout year” for the U.S. economy.
-
Issue of the week: Signs of a true recovery
feature Could the economy finally be back on track?
-
Issue of the week: The economy’s new normal
feature Are we in “a permanent slump?”
-
Issue of the week: When is inflation just right?
feature Though it has been battled in past decades, some economists believe a little inflation is good for a weak economy.
-
Issue of the week: The rise of a part-time economy
feature The economy has created new jobs for the 34th month in a row, but most of them are low-paid and part-time.
-
Issue of the week: A disappointing jobs report
feature The economy added just 88,000 jobs in March, less than half of Wall Street’s expectations.